真人做爰48姿势视图片|少妇真人直播免费视频|日本真人做爰A片|真人裸体做爰视频|真人与拘做爰视频免费观看|真人与拘做受免费视频一

FMS樣酪氨酸激酶3(Flt3)多克隆抗體(生物素標(biāo)記)

Biotin-Linked Polyclonal Antibody to FMS Like Tyrosine Kinase 3 (Flt3)

CD135; STK1; FLK2; Fms-Related Tyrosine Kinase 3; Stem Cell Tyrosine Kinase 1; FL Cytokine Receptor; Fetal Liver Kinase-2

  • FMS樣酪氨酸激酶3(Flt3)多克隆抗體(生物素標(biāo)記) 產(chǎn)品包裝(模擬)
  • FMS樣酪氨酸激酶3(Flt3)多克隆抗體(生物素標(biāo)記) 產(chǎn)品包裝(模擬)
  • Certificate 通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

特異性

該抗體是針對(duì)Flt3的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別Flt3。

用法

[ APPLICATIONS ]
Western blotting: 0.5-2ug/ml
Immunocytochemistry in formalin fixed cells: 5-20ug/ml
Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml
Immunohistochemistry in paraffin section: 5-20ug/ml
Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml
Optimal working dilutions must be determined by end user.

儲(chǔ)存

經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。

贈(zèng)品

相關(guān)產(chǎn)品

編號(hào) 適用物種:Mus musculus (Mouse,小鼠) 應(yīng)用(僅供研究使用,不用于臨床診斷!)
RPA039Mu01 FMS樣酪氨酸激酶3(Flt3)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAA039Mu01 FMS樣酪氨酸激酶3(Flt3)多克隆抗體 WB; IHC; ICC; IP.
LAA039Mu71 FMS樣酪氨酸激酶3(Flt3)多克隆抗體(生物素標(biāo)記) WB; IHC; ICC.

參考文獻(xiàn)

雜志 參考文獻(xiàn)
Frontiers in physiology Alpha-1 Antitrypsin Prevents the Development of Preeclampsia Through Suppression of Oxidative Stress [pubmed:27303303]
PLoS One Evaluation of surfactant proteins A, B, C, and D in articular cartilage, synovial membrane and synovial fluid of healthy as well as patients with osteoarthritis and?… [Pubmed: 30235245]
Bioscience Reports N-Acetylcysteine inhalation improves pulmonary function in patients received Liver Transplantation. [Doi: 10.1042/BSR20180858]
Molecular Neurobiology Elevated levels of multifunctional surfactant proteins in cerebrospinal fluid are associated with signs of increased cerebrospinal fluid flow in cranial magnetic?… [Doi: 10.1007/s12035-017-0835-5]
Cancers Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia [Pubmed: 31718075]
留言咨詢(xún)
迁西县| 澄城县| 祁连县| 海城市| 环江| 枝江市| 饶河县| 玉山县| 龙口市| 贵港市| 永仁县| 应用必备| 炉霍县| 临夏市| 大庆市| 濮阳市| 恩施市| 南城县| 东平县| 高安市| 高雄县| 衡阳市| 莎车县| 武汉市| 临安市| 喜德县| 乌兰浩特市| 通化市| 贵德县| 定边县| 海林市| 云霄县| 武强县| 梅州市| 马尔康县| 京山县| 喀喇| 嘉兴市| 桐梓县| 扶风县| 炎陵县|